News | March 27, 2014

Study Will Assess Defibrillator Therapy in Patients Most At-Risk for SCA

defibrillator, heart study
March 27, 2014 – Medtronic, Inc. announced the first patients were enrolled in the Improve SCA Clinical Study, a study that will identify patients in developing countries at high risk for sudden cardiac arrest (SCA)–an abrupt loss of heart function that can lead to death in minutes–who have not previously experienced a life threatening arrhythmia (primary prevention patients).  The first patients were enrolled at West China Hospital and Fuwai Hospital in China.
Patients enrolled in the study may be indicated for either an implantable cardioverter defibrillator (ICD), which administers electrical shocks or painless pacing therapy to stop the heart from quivering chaotically, or a CRT-D, which resynchronizes the contractions of the ventricles by sending tiny electrical impulses to the heart. Both devices are designed to stop a life-threatening fast or irregular heart rhythm that causes SCA, and are under-utilized in developing countries with typically less than 10 percent of indicated patients implanted.
"Defibrillation is the only definitive treatment for SCA, and while recent studies have proven ICDs are effective in reducing mortality for primary prevention patients in North America and Europe, our challenge has always been identifying those patients most at risk for SCA around the world," said Shu Zhang, M.D., of Fuwai Hospital in Beijing, China. "Improve SCA is the first study to evaluate the benefits of the therapy for high-risk patients in countries where defibrillation therapy for primary prevention of SCA is vastly underutilized."
It is estimated that 92 percent of people who suffer from sudden cardiac arrest will die within minutes without defibrillation. ICDs are 98 percent effective in stopping dangerous heart rhythms that can lead to Sudden Cardiac Death. 
"The study will provide the clinical evidence needed to help primary prevention patients at the highest risk of SCA access the therapy they need, and has the potential to eventually influence local guidelines," said Dejia Huang, M.D., of West China Hospital in Chengdu City, Sichuan Province, China.
The Improve SCA study will build local clinical evidence to identify already indicated ICD/CRT-D primary prevention patients with additional risk factors that put them at a highest risk for SCA, such as:
•         fainting (syncope),
•         rapid transient abnormal heartbeats starting in the bottom chambers of the heart (non-sustained ventricular tachycardia or frequent premature ventricular contractions),
•         or, decreased function of the heart (low ejection fraction).
The Improve SCA Clinical Study is expected to enroll approximately 4,800 participants that will be followed for two years. Approximately 100 sites will participate in more than 15 countries across Central and Eastern Europe (CEE), Asia, Middle East and Africa (MEA), India, and Latin America.  The study is a prospective, non-randomized, multicenter study that will assess patients meeting current Class I guidelines for ICD (or CRT-D) device implant as defined by the American College of Cardiology, American Heart Association, Heart Rhythm Society (ACC/AHA/HRS) or European Society of Cardiology (ESC).  
The study will test whether patients with a primary prevention indication for an ICD and one or more of these additional risk factors have the same risk of a having life threatening ventricular arrhythmia as those patients who have survived a prior episode of life threatening ventricular arrhythmia and are indicated for an ICD for secondary prevention of SCA.
"We are dedicated to improving the lives of patients most at risk for SCA and ensuring this patient population - which may benefit the most from defibrillation therapy - can get it," said Marshall Stanton, M.D., vice president and general manager of the tachycardia business at Medtronic. "While leveraging our global expertise, we work to identify challenges at the local level and become part of a long-term solution. Improve SCA is our latest study that aims to help even more patients access the most innovative, life-saving therapies available today."
Results from the study may help clinicians identify and refer primary prevention patients for ICD/CRT-D therapy, and help more patients make informed decisions about receiving a defibrillator. 
For more information:

Related Content

Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init